Featured Cancer Vaccine Technology

Creative Biolabs is committed to providing innovative, one-stop cancer vaccine technology services, covering the entire process from tumor antigen discovery and vaccine delivery system optimization to in-depth immune response monitoring. We utilize advanced platform technologies, including cell fusion, novel adjuvant development, immune suppression modulation, and biomarker discovery, to help researchers efficiently and flexibly develop next-generation tumor immunotherapies and expedite fundamental research and pre-discovery drug development.

Cancer Vaccine Technology: Concepts and Challenges

Cancer vaccine technology aims to train or enhance the body's own immune system (primarily T cells and B cells) using specific formulations or cells, enabling it to specifically recognize, attack, and eliminate tumor cells. This is an innovative strategy that leverages immunological memory to provide durable protection or therapeutic effect. Successful cancer vaccines can not only induce potent cellular immune responses but also establish long-term immune surveillance in research models, opening new directions for cancer treatment.

Key Issues to Consider in Research

Antigen Selection Specificity

Identifying tumor antigens (such as neoantigens) that elicit a powerful and specific immune response while avoiding autoimmunity is the primary challenge in vaccine design. This requires combining high-precision sequencing and bioinformatics prediction models to identify optimal immunogenic targets.

Tumor Microenvironment (TME) Immune Suppression

The TME is often highly immunosuppressive, rich in regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). Designing vaccines that can break through TME defenses and reverse the immunosuppressive state is a key factor affecting efficacy.

Optimization of Delivery Systems

Ensuring that the vaccine payload (e.g., peptides, DNA, RNA, or cells) is efficiently and stably taken up and activated by antigen-presenting cells (APCs) and effectively reaches the lymph nodes is the technical core for achieving an effective immune response. The choice of delivery vehicle (e.g., liposomes, nanoparticles) is critical.

Accurate Assessment of Immune Response

Precise and sensitive monitoring methods are needed to quantify the type (e.g., cytotoxic T cell activity, cytokine secretion profile) and strength of the immune response induced by the vaccine to guide subsequent optimization efforts. A lack of reliable biomarkers can hinder research progress.

Core Cancer Vaccine Development Technical Services

Immunogenicity Enhancement Vaccine Design

Utilizing advanced adjuvants and delivery strategies to maximize T cell activation, we design cancer vaccines with enhanced immunogenicity, laying a solid foundation for effective anti-tumor immune responses.

Immune Suppression Overcoming Service

With novel adjuvants and targeted strategies, we aim to reverse immune tolerance in the tumor microenvironment (TME), helping to break the immune suppression state and restore the body's anti-tumor immune function.

Comprehensive Immune Response Quantification Monitoring Platform

We provide an in-depth cellular and molecular functional data monitoring platform, enabling accurate quantification and analysis of the immune response induced by cancer vaccines, and providing reliable data support for vaccine optimization.

Therapeutic Target and Biomarker Discovery Acceleration Service

Guided by 'omics' technologies, we accelerate the discovery of potential therapeutic targets and biomarkers related to cancer vaccines, providing clear research directions for personalized cancer vaccine development.

Various Cancer Tumor Vaccine Technologies

Tumor-APC Fusion Technology: A cell vaccine strategy to enhance antigen cross-presentation. We fuse tumor cells with antigen-presenting cells (APCs) to present a more comprehensive tumor antigen profile.

Immune Monitoring Assay: High-throughput, multi-parameter immune response functional and cellular analysis. Provides precise flow cytometry and multiplex cytokine detection to quantify vaccine-induced immune responses.

Cytokine Development: Discovery, engineering, and production of key immune-modulating cytokines. Focused on developing and evaluating recombinant cytokines that enhance immune activation and T cell proliferation.

Anti-Treg Technology: Innovative targeting and inhibitory strategies for regulatory T cells (Treg). Aims to reduce immune suppression in the TME to improve vaccine efficacy.

Vaccine Combination Immunotherapy: Assessment of vaccines in combination with other immunotherapies (e.g., checkpoint inhibitors). Provides in vitro and in vivo combination study models to find potential synergistic effects.

Biomarker Discovery Technology: 'Omics'-based technology for discovering biomarkers of efficacy prediction and disease progression. Utilizes high-throughput screening and data analysis to identify molecular markers related to vaccine response.

Microfluidic Cell Squeezing Technology: A high-efficiency intracellular delivery platform. Gently introduces macromolecules (e.g., mRNA) into immune cells via mechanical deformation to increase transfection efficiency.

Antibody-Antigen Fusion Technology: Fusion protein design for targeted antigen delivery to APCs. Achieves high-specificity delivery of antigens to the surface of immune cells by linking antibodies and antigens.

MHC Class II associated li Protein Suppression Technology: Molecular technology for modulating antigen presentation processes to enhance immunogenicity. Optimizes the presentation efficiency of antigens by MHC Class II molecules by regulating the expression or function of the li protein.

Toll-Like Receptor 9 Agonist Development Technology: Develops CpG oligonucleotides to activate TLR9, inducing Th1-type immune responses and enhancing vaccine adjuvancy.

Our Technical Pillars

High-Throughput Antigen Screening

Utilizing advanced Next-Generation Sequencing (NGS), AI, and machine learning algorithms to accelerate the identification, prediction, and validation of neoantigens and Tumor-Associated Antigens (TAAs), focusing on identifying peptides with the strongest T cell immunogenicity.

Multi-Modal Vaccine Preparation

Offering flexible preparation services supporting complex vaccine forms such as peptides, recombinant proteins, various nucleic acids (including mRNA/DNA vectors), engineered viral vectors, and autologous/allogeneic cells (e.g., DC, fusion cells) for design and optimization.

In Vitro Immune Function Analysis

Providing high-dimensional flow cytometry (up to 30 colors), mass spectrometry-based multiplex cytokine detection, and intracellular cytokine staining to deeply analyze immune cell activity, phenotype, and functional status.

Service Workflow: From Target to Validation

Target Identification and Antigen Screening

Utilizing bioinformatics tools and multi-omics data (genomics, transcriptomics) to perform high-precision prediction and screening of tumor-specific or neoantigens. Goal: To ensure the selection of the most immunogenic and specific targets and conduct MHC binding affinity prediction, laying a solid foundation for subsequent vaccine design.

Vaccine Design and Formulation Optimization

Based on target properties, designing the optimal vaccine platform (e.g., peptide, nucleic acid, cell). Focus on optimizing the vaccine structure, selecting and integrating novel adjuvants, and optimizing the delivery system (e.g., liposomes or nanoparticles) to maximize its stability and immune activation capability in research models.

Functional Validation and Immune Response Assessment

Validating the vaccine's antigen presentation efficiency and T cell activation capability in in vitro models (such as DC-T cell co-culture systems). Comprehensive analysis of immune cell types, cytokine profiles, and cytotoxic activity using advanced immune monitoring techniques to assess vaccine effectiveness.

Results Analysis and Iterative Optimization

Providing detailed experimental data and analysis reports, including comprehensive charts and data visualization. Based on experimental results, collaborating with clients to suggest potential optimization directions and rapidly iterating and improving the vaccine structure, dosage, or immunization strategy for better research outcomes.

Partner with Creative Biolabs Now!

Unique Advantages of Creative Biolabs

Integrated Platform

We offer complete integrated solutions from target discovery and vector construction to immune assessment, ensuring seamless transitions between different modules and greatly enhancing R&D efficiency and data consistency.

Technical Innovativeness

We continuously invest in cutting-edge technologies, including advanced microfluidic delivery systems, high-affinity fusion protein design, and novel immune checkpoint modulation strategies, ensuring client research remains at the forefront of the industry.

High Customization

Our services are not "one-size-fits-all" standard products. We provide flexible adjustments and deeply customized experimental protocols and reports based on clients' specific tumor antigens, genetic backgrounds, and research objectives.

Focus on Delivery Timeliness

Through optimized project management processes and dedicated project managers, we ensure efficient project progression and the high-quality delivery of data and experimental materials within the agreed-upon timeframe.

A slide highlighting the Advantages of Creative Biolabs related to featured cancer vaccine technologies.

Customer Reviews

"We used Creative Biolabs' Tumor-APC Fusion Technology platform. The cell vaccine they delivered demonstrated excellent antigen presentation efficiency, and cell viability was well-maintained. The project progress was much faster than we expected, significantly advancing our basic research process."

— Dr. Chen,

Director of Immunology Research Center

"In complex immune monitoring assays, the Creative Biolabs team demonstrated outstanding expertise and data interpretation capabilities. The multiplex cytokine data they provided was accurate and detailed, especially the precise quantification of Th1/Th2 polarization and Treg cell populations, which was crucial for evaluating the inhibitory effects induced by our vaccine."

— Jane M.,

Senior Scientist, Biotechnology Company

"The Biomarker Discovery Technology service helped us rapidly narrow down the range of potential prognostic markers. Their solution was highly flexible and perfectly matched our small-scale initial research needs, and the data was highly interpretable, saving us a lot of subsequent validation work."

— Professor Li,

PI, Tumor Biology Laboratory

Case Study

Senecavirus A (SVA) CH-GX-01-2019 Inactivated Vaccine Immunogenicity Evaluation

Background

This study aimed to evaluate the immunogenicity of an SVA inactivated vaccine (CH-GX-01-2019 strain) with different adjuvants, addressing SVA’s threat of causing swine vesicular disease (clinically indistinguishable from FMDV) and the lack of approved vaccines to protect pig herds.

Solution

SVA was inactivated with binary ethylenimine. Mice (C57BL/6) were grouped (PBS, SVA alone, SVA+aluminum adjuvant, SVA+oil-in-water adjuvant) and pigs (post-weaned) into 4 groups (PBS, SVA-L:50μg+oil-in-water adjuvant, SVA-H:200μg+oil-in-water adjuvant). All were immunized twice (0/21 dpv). Immunogenicity was assessed via VNT (neutralizing antibodies), ELISA (total IgG, IgG subtypes, IL-4/IFN-γ).

Result

In mice, SVA+oil-in-water adjuvant induced higher neutralizing antibodies (21-35 dpv) and IL-4/IFN-γ than SVA+aluminum adjuvant; both adjuvant groups had higher IgG/IgG subtypes than SVA alone. In pigs, SVA-L/SVA-H induced high neutralizing antibodies (peaking at 35 dpv) and total IgG (7 dpv detectable); SVA-H had higher IFN-γ, confirming robust immunogenicity.

A slide displaying the evaluation of the immunogenicity of the SVA Inactivated Vaccine in mice.

Evaluation of the Immunogenicity of the SVA Inactivated Vaccine in Mice.
Zhang, Jinyong, et al. "Adjuvant screening of the Senecavirus A inactivated vaccine in mice and evaluation of its immunogenicity in pigs." BMC Veterinary Research 20.1 (2024): 82. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12917-024-03949-5

Cancer Vaccine Technology Frequently Asked Questions

Which types of cancer vaccine research does Creative Biolabs primarily support?

We support the development and research of various vaccine types, including those based on synthetic peptides, recombinant proteins, nucleic acids (DNA/mRNA), engineered viral vectors, and various forms of cell vaccines. Our services cover customized needs from early antigen design to late-stage in vitro functional validation.

What key data does the immune monitoring assay service provide?

We provide quantitative data on immune cell phenotype analysis (e.g., CD4+/CD8+ T cell ratios), cytokine release profiles, antibody titers, and Cytotoxic T Lymphocyte (CTL) killing activity. This data is used for a comprehensive assessment of the strength and nature of the immune response induced by the vaccine.

If my project needs to overcome immune suppression, what specific technical support do you offer?

We offer Anti-treg technology and vaccine combination immunotherapy strategies. These services aim to enhance immune activation by targeting or inhibiting the function of immunosuppressive cells, or by evaluating the synergistic effects of combining vaccines with novel immune modulators.

How do you ensure the antigen purity for cancer vaccine preparation?

We employ multi-step purification protocols and a strict quality control system for antigen preparation. For peptides and recombinant proteins, high-performance liquid chromatography (HPLC) is used for fine separation, and qualitative/quantitative verification is performed via SDS-PAGE and mass spectrometry, ensuring high purity and activity of the delivered antigens to support reliable downstream research.

What are the application scenarios for Microfluidic Cell Squeezing Technology?

This technology is mainly applied in cell engineering, particularly in non-viral vector systems. It uses gentle mechanical squeezing through microfluidic channels to deliver large molecules (e.g., mRNA, proteins) efficiently and with low toxicity into primary immune cells (such as DC or T cells), making it an important tool for constructing engineered cell vaccines in vitro.

Consult Creative Biolabs on Unique Cancer Vaccine Technology Platforms!

Creative Biolabs is more than just a service provider; we are a pioneer in innovative cancer vaccine technologies. We offer a suite of unique, highly specialized platforms designed to resolve challenges related to low immunogenicity, immune suppression, and delivery, ensuring your customized vaccine project achieves maximum potency.

Schedule Your Consultation

Featured Resources

Reference image of vaccine-resources-1, containing materials relevant to vaccine research and development.

Download Resources

Visual of vaccine-literature-1, representing academic or technical literature focused on vaccine studies.